Reteplase: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug pregnan...") |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: [[Thrombolytic]] | ||
*Dosage Forms: | *Dosage Forms: injection | ||
*Routes of Administration: | *Routes of Administration: IV | ||
*Common Trade Names: | *Common Trade Names: Retavase | ||
==Indications== | |||
*Thrombolysis in [[STEMI]] | |||
==Adult Dosing== | ==Adult Dosing== | ||
*10 units IVx2 | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Not approved for use in pediatrics | |||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | ===[[Drug pregnancy categories|Pregnancy Rating]]=== | ||
* | *Category C | ||
===Lactation risk=== | ===Lactation risk=== | ||
* | *Caution advised while breastfeeding | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*Adult: | *Adult: n/a | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*Adult: | *Adult: n/a | ||
==Contraindications== | ==Contraindications== | ||
| Line 31: | Line 32: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*[[Intracranial hemorrhage]] | |||
*Severe bleeding | |||
*Reperfusion arrhythmia | |||
*Hypersensitivity reaction | |||
*Cholesterol embolism | |||
===Common=== | ===Common=== | ||
*Bleeding | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 13-16 min | ||
*Metabolism: | *Metabolism: Liver, kidney | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Binds to fibrin, converts tissue plasminogen to plasmin, promoting thrombolysis<ref>Reteplase [monograph]. Epocrates Version. 20.2 [iPhone]. Epocrates, Inc, San Francisco, CA. Available from https://online.epocrates.com/. Accessed March 26, 2020.</ref> | |||
==See Also== | ==See Also== | ||
*[[Thrombolytics]] | |||
*[[Tenecteplase]] | |||
Latest revision as of 21:34, 26 March 2020
Administration
- Type: Thrombolytic
- Dosage Forms: injection
- Routes of Administration: IV
- Common Trade Names: Retavase
Indications
- Thrombolysis in STEMI
Adult Dosing
- 10 units IVx2
Pediatric Dosing
- Not approved for use in pediatrics
Special Populations
Pregnancy Rating
- Category C
Lactation risk
- Caution advised while breastfeeding
Renal Dosing
- Adult: n/a
Hepatic Dosing
- Adult: n/a
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Intracranial hemorrhage
- Severe bleeding
- Reperfusion arrhythmia
- Hypersensitivity reaction
- Cholesterol embolism
Common
- Bleeding
Pharmacology
- Half-life: 13-16 min
- Metabolism: Liver, kidney
Mechanism of Action
- Binds to fibrin, converts tissue plasminogen to plasmin, promoting thrombolysis[1]
See Also
References
- ↑ Reteplase [monograph]. Epocrates Version. 20.2 [iPhone]. Epocrates, Inc, San Francisco, CA. Available from https://online.epocrates.com/. Accessed March 26, 2020.